共 170 条
[1]
Couec ML(2012)Comité Pharmacologie of the SFCE (2012) Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends Pediatr Blood Cancer 59 34-385
[2]
André N(2009)Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan Pediatr Blood Cancer 52 791-795
[3]
Thebaud E(2014)Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a pediatric brain tumor consortium study Neuro-Oncology 16 310-317
[4]
Packer RJ(2015)Confirmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma J Pediatr Hematol Oncol 37 341-346
[5]
Jakacki R(2013)Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience Childs Nerv Syst 29 589-596
[6]
Horn M(2011)Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen J Neuro-Oncol 103 673-680
[7]
Rood B(2015)Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma Pediatr Int 57 169-1718
[8]
Vezina G(1995)Clinical applications of research on angiogenesis N Engl J Med 333 1757-1763
[9]
MacDonald T(2003)The biology of VEGF and its receptors Nat Med 9 669-676
[10]
Fisher MJ(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342